Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2024

  • receipt Report ID : 159908
  • calendar_today Published On: Apr, 2019
  • file_copy Pages: 120
  • list Pharmaceuticals and Healthcare

Gastroesophageal reflux disease (GERD), also known as acid reflux, is a long-term condition where stomach contents come back up into the esophagus resulting in either symptoms or complications.

Scope of the Report:

This report studies the Gastroesophageal Reflux Disease (GERD) Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Gastroesophageal Reflux Disease (GERD) Therapeutics market by product type and applications/end industries.

Patent expiry of blockbuster drugs prescribed for the treatment of acid reflux disorders is majorly attributable for the downfall of this market.

The global Gastroesophageal Reflux Disease (GERD) Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Gastroesophageal Reflux Disease (GERD) Therapeutics.

Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

Market Segment by Companies, this report covers

AstraZeneca

Eisai

GSK

Takeda

Johnson & Johnson

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Antacids

Pro-kinetic agents

H2 Receptor Blockers

Proton Pump Inhibitors (PPIs)

Market Segment by Applications, can be divided into

Heartburn

Acid reflux disorders

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Gastroesophageal Reflux Disease (GERD) Therapeutics Market Overview

1.1 Product Overview and Scope of Gastroesophageal Reflux Disease (GERD) Therapeutics

1.2 Classification of Gastroesophageal Reflux Disease (GERD) Therapeutics by Types

1.2.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Comparison by Types (2017-2023)

1.2.2 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Types in 2017

1.2.3 Antacids

1.2.4 Pro-kinetic agents

1.2.5 H2 Receptor Blockers

1.2.6 Proton Pump Inhibitors (PPIs)

1.3 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market by Application

1.3.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)

1.3.2 Heartburn

1.3.3 Acid reflux disorders

1.4 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market by Regions

1.4.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)

1.4.1 North America (USA, Canada and Mexico) Gastroesophageal Reflux Disease (GERD) Therapeutics Status and Prospect (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy) Gastroesophageal Reflux Disease (GERD) Therapeutics Status and Prospect (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Gastroesophageal Reflux Disease (GERD) Therapeutics Status and Prospect (2013-2023)

1.4.4 South America (Brazil, Argentina, Colombia) Gastroesophageal Reflux Disease (GERD) Therapeutics Status and Prospect (2013-2023)

1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Gastroesophageal Reflux Disease (GERD) Therapeutics Status and Prospect (2013-2023)

1.5 Global Market Size of Gastroesophageal Reflux Disease (GERD) Therapeutics (2013-2023)

2 Manufacturers Profiles

2.1 AstraZeneca

2.1.1 Business Overview

2.1.2 Gastroesophageal Reflux Disease (GERD) Therapeutics Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 AstraZeneca Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.2 Eisai

2.2.1 Business Overview

2.2.2 Gastroesophageal Reflux Disease (GERD) Therapeutics Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Eisai Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.3 GSK

2.3.1 Business Overview

2.3.2 Gastroesophageal Reflux Disease (GERD) Therapeutics Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 GSK Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.4 Takeda

2.4.1 Business Overview

2.4.2 Gastroesophageal Reflux Disease (GERD) Therapeutics Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Takeda Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.5 Johnson & Johnson

2.5.1 Business Overview

2.5.2 Gastroesophageal Reflux Disease (GERD) Therapeutics Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Johnson & Johnson Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

3 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Competition, by Players

3.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Share by Players (2013-2018)

3.2 Market Concentration Rate

3.2.1 Top 5 Gastroesophageal Reflux Disease (GERD) Therapeutics Players Market Share

3.2.2 Top 10 Gastroesophageal Reflux Disease (GERD) Therapeutics Players Market Share

3.3 Market Competition Trend

4 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Regions

4.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Market Share by Regions

4.2 North America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2013-2018)

4.3 Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2013-2018)

4.4 Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2013-2018)

4.5 South America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2013-2018)

4.6 Middle East and Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2013-2018)

5 North America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Countries

5.1 North America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Countries (2013-2018)

5.2 USA Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2013-2018)

5.3 Canada Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2013-2018)

5.4 Mexico Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2013-2018)

6 Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Countries

6.1 Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Countries (2013-2018)

6.2 Germany Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2013-2018)

6.3 UK Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2013-2018)

6.4 France Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2013-2018)

6.5 Russia Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2013-2018)

6.6 Italy Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2013-2018)

7 Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Countries

7.1 Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Countries (2013-2018)

7.2 China Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2013-2018)

7.3 Japan Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2013-2018)

7.4 Korea Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2013-2018)

7.5 India Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2013-2018)

7.6 Southeast Asia Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2013-2018)

8 South America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Countries

8.1 South America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Countries (2013-2018)

8.2 Brazil Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2013-2018)

8.3 Argentina Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2013-2018)

8.4 Colombia Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2013-2018)

9 Middle East and Africa Revenue Gastroesophageal Reflux Disease (GERD) Therapeutics by Countries

9.1 Middle East and Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue by Countries (2013-2018)

9.2 Saudi Arabia Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2013-2018)

9.3 UAE Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2013-2018)

9.4 Egypt Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2013-2018)

9.5 Nigeria Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2013-2018)

9.6 South Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Growth Rate (2013-2018)

10 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Segment by Type

10.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue and Market Share by Type (2013-2018)

10.2 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Forecast by Type (2018-2023)

10.3 Antacids Revenue Growth Rate (2013-2023)

10.4 Pro-kinetic agents Revenue Growth Rate (2013-2023)

10.5 H2 Receptor Blockers Revenue Growth Rate (2013-2023)

10.6 Proton Pump Inhibitors (PPIs) Revenue Growth Rate (2013-2023)

11 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Segment by Application

11.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Share by Application (2013-2018)

11.2 Gastroesophageal Reflux Disease (GERD) Therapeutics Market Forecast by Application (2018-2023)

11.3 Heartburn Revenue Growth (2013-2018)

11.4 Acid reflux disorders Revenue Growth (2013-2018)

12 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size Forecast (2018-2023)

12.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size Forecast (2018-2023)

12.2 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Forecast by Regions (2018-2023)

12.3 North America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Forecast (2018-2023)

12.4 Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Forecast (2018-2023)

12.5 Asia-Pacific Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Forecast (2018-2023)

12.6 South America Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Forecast (2018-2023)

12.7 Middle East and Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue Market Forecast (2018-2023)

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source

List of Tables and Figures

Figure Gastroesophageal Reflux Disease (GERD) Therapeutics Picture

Table Product Specifications of Gastroesophageal Reflux Disease (GERD) Therapeutics

Table Global Gastroes

Please fill the form below, to recieve the report sample


+1